ERBB2 and neoplasm: Moreover, trastuzumab could enhance the efficacy of immune checkpoint inhibitors through increasing HER2 internalization and cross-presentation by dendritic cells (20), upregulating PD-1 and PD-L1 expression, inducing the expansion of tumor-specific CD4 and CD8 T cells and MHC class II expression (11, 12, 21).